BOTHELL, WA, and VANCOUVER, May 17 /CNW/ - OncoGenex Pharmaceuticals,
Inc. (NASDAQ: OGXI) announced today that Cameron Lawrence, OncoGenex'
Director of Finance and Principal Accounting Officer, will be
presenting at the UBS Global Specialty Pharmaceuticals Conference on
Wednesday, May 25 at 10:00 a.m. BST (5:00 a.m. ET). The conference
takes place at the UBS offices in London.
The live audio webcast can be accessed through the Investor Relations
page of the OncoGenex website at www.oncogenex.com. A webcast replay will be available approximately one hour after the
live webcast concludes and will be archived for 90 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new cancer therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NASDAQ: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer.
The companies plan to begin Phase 3 development of custirsen in
first-line treatment of advanced, unresectable non-small cell lung
cancer in 2011. OGX-427 is in Phase 2 clinical development; and
CSP-9222 and OGX-225 are currently in pre-clinical development.
More information about OncoGenex is available at www.oncogenex.com.
SOURCE OncoGenex Pharmaceuticals, Inc.
For further information: